A Retrospective Drug Utilization Study of Antiplatelet Drugs in Patients with Ischemic Heart Disease

Authors: K. Jyothi, T. S. Mohamed Saleem, L. Vineela, C. Gopinath, K. B. Yadavender Reddy

Abstract:

Objective: Acute coronary syndrome is a clinical condition encompassing ST segments elevation myocardial infraction, Non ST segment is elevation myocardial infraction and un stable angina is characterized by ruptured coronary plaque, stress and myocardial injury. Angina pectoris is a pressure like pain in the chest that is induced by exertion or stress and relived with in the minute after cessation of effort or using sublingual nitroglycerin. The present research was undertaken to study the drug utilization pattern of antiplatelet drugs for the ischemic heart disease in a tertiary care hospital. Method: The present study is retrospective drug utilization study and study period is 6months. The data is collected from the discharge case sheet of general medicine department from medical department Rajiv Gandhi institute of medical sciences, Kadapa. The tentative sample size fixed was 250 patients. Out of 250 cases 19 cases was excluded because of unrelated data. Results: A total of 250 prescriptions were collected for the study according to the inclusion criteria 233 prescriptions were diagnosed with ischemic heart disease 17 prescriptions were excluded due to unrelated information. out of 233 prescriptions 128 are male (54.9%) and 105 patients are were female (45%). According to the gender distribution, the prevalence of ischemic heart disease in males are 90 (70.31%) and females are 39 (37.1%). In the same way the prevalence of ischemic heart disease along with cerebrovascular disease in males are 39 (29.6%) and females are 66 (62.6%). Conclusion: We found that 94.8% of drug utilization of antiplatelet drugs was achieved in the Rajiv Gandhi institute of medical sciences, Kadapa from 2011-2012.

Keywords: Angina pectoris, aspirin, clopidogrel, myocardial infarction.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1110808

References:

[1] Najeeb, Q., S. Hamid, A.H. Khan. 2014. Novel Biomarkers in Assessing Cardiovascular Status in Acute Myocardial Infarction. J. Cardiovas. Dis. Res. 5(4): 22-27.
[2] Kristian, T., S.A. Joseph, S.J. Allan, L.S. Maarten, R.C. Bernard, D.W. Harvey. 2012. Third Universal Definition of Myocardial Infarction. J. Am. Coll. Cardiol. 60(16):1581-98.
[3] Indrayan A. 2004. Forecasting cardiovascular disease cases and associated mortality in India. National Commission for Macroeconomics and Health, Government of India: New Delhi. 3.
[4] Enas, E.A., S. Kannan. 2008. How to beat the heart disease epidemic among South Asians. A prevention and management guide for Asian Indians and their doctors. Downers Grove: Advanced Heart Lipid Clinic USA, 2007. Indian Heart J 60: 161–175.
[5] Ajay, S.V., D. Prabhakaran. 2010. Coronary Heart Disease in Indias. Implications of the INTERHEART study. Indian Journal of Medical Research 132: 561-566.
[6] Fahimi, F., S. Baniasadi, N. Behzadniac, F. Varahrama, L.G. Tabatabaie. 2008. Enoxaparin Utilization Evaluation: An Observational Prospective Study in Medical Inpatients. Iranian. J. Pharmaceutical. Res. 7 (1): 77-82
[7] WHO 2014, http://apps.who.int/medicinedocs/en/d/Js4876e
[8] John, L.J., P. Devi, S. Guido. 2012. Utilization of antihypertensive medications among the critically ill patients. RJPBCS 3(3):650-654
[9] WHO 2011. Cardiovascular diseases (CVDs) Fact sheet No. 317, September.
[10] Ajay, S.V., Prabhakaran, D. 2010. Coronary Heart Disease in Indias. Implications of the INTERHEART study. Indian Journal of Medical Research 132: 561-566.
[11] Balady, G.J., Williams, M.A., Ades, P.A., Bittner, V., Comoss, P., Foody, J.A.M. 2007. Core components of cardiac rehabilitation/secondary prevention programs. Circulation 115: 2675– 2682.
[12] Fox, K. 2008. Stable angina pectoris. In: Compendium of Abridged ESC Guidelines. Nice, France: European Society of Cardiology pp 77–89.
[13] National Institute of Clinical Excellence 2007. CG48. MI: Secondary prevention: understanding NICE guidelines.
[14] World Health Organisation. 2002. Wellcome Trust Meeting Report. Secondary prevention of non-communicable diseases in low and middle income countries through community-based and health service interventions. WHO Document No. WHO/EDM/2000. Geneva, Switzerland: World Health Organization.
[15] Beaglehole, R., Epping-Jordan, A., Patel, V., Chopra, M., Ebrahim, S., Kidd, M., Haines, A. 2008. Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. Lancet 372: 940–949.
[16] De Wilde, S., Carey, I.M., Richards, N., Whincup, P.H., Cook, D.G. 2008. Trends in secondary prevention of ischemic heart disease in the UK 1994–2005: use of individual and combination treatment. Heart 94: 83–88.
[17] Newby, L.K., LaPointe, N.M.A., Chen, A.Y., Kramer, J.M., Hammill, B.G., DeLong, E.R. 2006. Long term adherence to evidence based secondary prevention therapies in coronary artery disease. Circulation 113: 203–212.
[18] Chauhan, S., Aeri, B.T. 2013. Prevalence of cardiovascular disease in India and it is economic impact- A review. Int. J. Sci. Res. Pub. 3(10):1- 5.
[19] Padmavati, S. 2014. Epidemiology of Cardiovascular Disease in India. J. American. Heart. Association. 711-717.
[20] Sandozi, T., Nausheen, F. 2010. Drug utilization study in ischemic heart diseases associated with diabetes and hypertension. Int. J. Pharma. Bio. Sci. 1 (3):1-4.
[21] Jhaveri, B. N., Patel, T. K., Barvaliya, M. J., & Tripathi, C. B. 2014. Drug utilization pattern and pharmacoeconomic analysis in geriatric medical in-patients of a tertiary care hospital of India. Journal of Pharmacology & Pharmacotherapeutics, 5(1), 15–20. http://doi.org/10.4103/0976-500X.124411
[22] Ghosh, A., Kumar, A. 2012. Drug utilization study in patients of acute coronary syndrome on follow-u visits at a tertiary care centre in Kolkata. Asian. J. Pharmacy. Life. Science. 2(2): 155-165.